Eli Lilly Aktie
WKN: 858560 / ISIN: US5324571083
| 23.01.2025 12:17:00 | 
Eli Lilly Shares Fall After GLP-1 Sales Miss Expectations. Is the Stock in Trouble?
		Eli Lilly  (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, has helped boost its market capitalization to around $650 billion. Over the last five years, shares have soared by more than 400%.Recently, however, the stock has been struggling; in the past three months, Lilly's valuation has declined by 21%. It fell last week after the company released updated guidance, with revenue for its GLP-1 drugs projected to come in below expectations for the most recent quarter.Is this a sign the stock is in trouble and likely headed for more of a decline this year? Or could now be a good time to buy Eli Lilly  on the dip?Continue readingWeiter zum vollständigen Artikel bei MotleyFool 
	
	
	 Der finanzen.at Ratgeber für Aktien!
						
						
						
							
								Der finanzen.at Ratgeber für Aktien!
							
							Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Eli Lillymehr Nachrichten
Analysen zu Eli Lillymehr Analysen
| 20.12.24 | Eli Lilly Buy | Jefferies & Company Inc. | |
| 31.10.24 | Eli Lilly Buy | Jefferies & Company Inc. | |
| 13.02.24 | Eli Lilly Buy | Jefferies & Company Inc. | 
Aktien in diesem Artikel
| Eli Lilly | 734,00 | 0,33% |  | 
 
									 
									 
								